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Abstract
Background: Decision-making about appropriate therapy to reduce the stroke risk associated with non-valvular
atrial fibrillation (NVAF) involves the consideration of trade-offs among the benefits, risks, and inconveniences of
different treatment options. The objective of this paper is to describe the development of a decision support tool
for NVAF based on the provision of individualized risk estimates for stroke and bleeding and on preparing patients
to communicate with their physicians about their values and potential treatment options.
Methods: We developed a tool based on the principles of the International Patient Decision Aids Standards. The
tool focuses on the patient-physician dyad as the decision-making unit and emphasizes improving the interaction
between the two. It is built on the recognition that the application of patient values to a specific treatment
decision is complex and that the final treatment choice is best made through a process of patient-clinician
communication.
Results: The tool provides education incorporating patients ‘ illness perceptions to explain the relationship
between NVAF and stroke, and then presents individualized risk estimates, derived using separate risk calculators
for stroke and bleeding over a clinically meaningful time period (5 years) associated with no treatment, aspirin, and
warfarin. Sequelae of both stroke and bleeding outcomes are also described. Patients are encouraged to verbalize
how they value the incremental risks and benefits associated with each option and write down specific concerns
to address with their physician. A physician prompt to encourage patients to discuss their opinions is included as
part of the decision support tool. In pilot testing with 11 participants (mean age 78 ± 9 years, 64% with ≤ high-
school education), 8 (72%) rated ease of completion as “very easy,” and 9 (81%) rated amount of information as
“just right.”
Conclusions: The risks and benefits of different treatment options for reduction of stroke in NVAF vary widely
according to patients’ comorbidities. This tool facilitates the provision of individualized outcome data and
encourages patients to communicate with their physicians about these risks and benefits. Future studies will
examine whether use of the tool is associated with improved quality of decision making.
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Background
Nonvalvular atrial fibrillation (NVAF) is associated with
an increased risk of stroke. Several randomized con-
trolled trials have demonstrated a reduction in risk of
future stroke with oral anticoagulants and antiplatelet
agents, but at an increased risk of bleeding [1]. Deci-
sion-making about appropriate therapy to reduce this
stroke risk involves the consideration of trade-offs
among the benefits, risks, and inconveniences of differ-
ent treatment options.
Guidelines addressing NVAF recommend the use of
warfarin in patients with NVAF at high risk for stroke
and aspirin for patients at lower risk [2,3]. However,
both stroke and bleeding risk vary widely according to
each patient’s specific comorbidities [4,5]. Because of
this variability in risk, there is a large range in the incre-
mental risks and benefits associated with warfarin,
aspirin and, no treatment [6]. Moreover, a review of
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ment for NVAF concluded that patient preferences fre-
quently differ from treatment recommendations provided
by guidelines [7]. Because of the variability in outcomes
and preferences for the treatment of NVAF, the decision
to initiate and maintain anticoagulation should ideally be
based on a consideration of individualized outcome data
and how patients value these outcomes [6].
Several decision aids have been developed to provide
patients with information regarding risks and benefits of
aspirin and warfarin and to help patients clarify their
preferences regarding these options [8-10]. These aids,
while stratifying patients’ risk of stroke according to
their comorbidities, have either not similarly stratified
patients’ risk of bleeding or have stratified bleeding risk
for warfarin according to limited patient characteristics.
In addition, existing decision aids have generally focused
on the provision of information to patients. However,
the provision of information, while necessary, is often
not sufficient to improve the process of decision making
[11]. To ensure informed choice, patients must be able
be to effectively communicate their questions, concerns,
and preferences to their physicians. In this paper we
describe the development of comprehensive decision
tool that focuses on preparing the patients to communi-
cate with his/her physician to improve the quality of
decision making in NVAF.
Methods
The tool was designed to conform to the International
Patient Decision Aids Standards (IPDAS) [12]. These
criteria informed the process of tool development and
the content, in terms of the description of treatment
options, presentation of outcome probabilities, and help-
ing patients to clarify their values. In addition to these
criteria, development was guided by the conceptual
model illustrated in Figure 1, which highlights the need
to prepare patients to participate in the decision making
process by helping them to understand the availability
of options and the role of values and to communicate
effectively with their clinicians, taking into account indi-
vidual variability in preferred decision-making style.
Results
Tool development occurred in an iterative process, in
which the tool was administered to several participants,
who were encouraged to ask questions and provide
comments. The research assistant periodically assessed
participants’ understanding and recorded both partici-
pant feedback and her own observations, and these were
used to make revisions to the tool. The revised version
was then administered to the next group of participants,
in order to elicit another round of feedback. This pro-
cess continued until no additional clarifications were
needed. This process led to several fundamental
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Figure 1 Conceptual model guiding design of tool.
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Page 2 of 10contributions to tool development: 1) participants found
it difficult to understand how a problem in the heart
could cause a problem in the brain. We therefore sought
to create an educational component based on patients’
illness perceptions; 2) in order to keep participants
engaged, they required opportunities to think aloud
about the material they were seeing and to interact with
the research assistant.
The rational justifying each component is described in
the following sections.
Mode of Employment
The decision tool was designed to be used immediately
prior to a regularly scheduled health maintenance
appointment in a primary care setting, using a laptop
computer and administered by a trained facilitator,
using a script that is read word-for-word. Although the
most appropriate time to implement decision support
for NVAF may be at the time of diagnosis, in many set-
tings the incidence of new NVAF is too low and the sys-
tem barriers too numerous to introduce a decision
support tool at the time of diagnosis. We therefore
developed the tool to address prevalent NVAF, which
allows the physician and patient to re-examine treat-
ment decision-making as patients’ risk factors for stroke
and bleeding change over time.
Enhancing Understanding of NVAF
Effectively informing patients requires that patients have
accurate illness perceptions about the cause of stroke in
NVAF [13]. We therefore included the following educa-
tional component:
“T o d a yw ea r eg o i n gt ob et a l k i n ga b o u ta t r i a l
fibrillation, which I will be referring to as AFib.
Afib is a heart problem. It’sn o tt h es a m eh e a r tp r o -
blem that gives you a heart attack. Even though
Afib is a heart problem it can cause a stroke. Peo-
ple generally think that heart diseases only cause
problems in the chest.”
Using a picture demonstrating the relationship
between the brain and the heart taken from the NHLBI
patient information website (Figure 2), [14] the research
assistant then points out the connection of the heart to
the brain:
“People generally think that heart diseases only cause
problems in the chest. But this picture shows you why
atrial fibrillation can cause a stroke. As you can see
the heart is connected to the brain by a big blood
vessel. Afib can cause blood clots in the heart. These
clots can travel up the blood vessel to the brain and
cut off the blood supply to a part of the brain. This
causes a stroke”.
Presentation of Individualized Treatment Choices and
Outcomes
In NVAF, the benefits (i.e. stroke risk reduction) and
harms (i.e. increased bleeding risk) of treatment vary
considerably, such that the benefit to harm ratio can
actually reverse according to the patients’ specific
comorbid conditions [6]. In addition, age and comorbid-
ity confer a baseline bleeding risk, [15] which, if not
accounted for, results in an overestimation of the bleed-
ing risk associated with treatment. The varying likeli-
hoods of benefits and harms highlights the need for
providing patients with individualized risk estimates, cal-
culated separately for bleeding and stroke risk.
We searched for validated risk calculators that would
allow us to present patients with individualized outcome
data. Of the two calculators identified for baseline stroke
risk in NVAF, [4,16] we elected to use the CHADS2
algorithm (congestive heart failure, hypertension, age,
diabetes, stroke) because it was developed in a cohort
with prevalent rather than incident NVAF. The relative
reduction in stroke risk associated with aspirin (21%)
and with warfarin (67%) as compared to no treatment
were taken from a meta-analysis of randomized
Figure 2 Picture used to facilitate pathophysiology of stroke in
NVAF.
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calculators for bleeding risk associated with warfarin,
[5,17,18] we elected to use the HEMORR2HAGES score
[5] (hepatic or renal disease, ethanol abuse, malignancy,
older age, reduced platelet count or function, hyperten-
sion [uncontrolled], anemia, genetic factors, excessive
fall risk, and stroke) because it was derived from popu-
lation-level data, as compared to data derived from sin-
gle-site studies, and provides the greatest the greatest
range of bleeding risk, with the ability to discriminate
risks within this range.
T h e r ew e r es u r p r i s i n g l yl i t t l ed a t ar e g a r d i n ga b s o l u t e
rates of baseline bleeds and risk factors associated with
baseline and aspirin associated bleeding risk. Although
observational studies of NSAID-associated bleeding fre-
quently include additional bleeding risk factors, the con-
trol groups for these studies generally include persons
who are taking aspirin, so that they cannot provide an
estimate of baseline bleeding risk. The algorithm for
baseline bleeding risk stratification was based on meta-
analysis of studies in which aspirin use was well charac-
terized [15]. A literature search failed to turn up risk
prediction tools for bleeding on aspirin and revealed a
wide range of estimates for aspirin’s effect on bleeding
risk. The most comprehensive systematic review of 17
epidemiologic (observational) studies provided a pooled
relative risk for aspirin-associated bleeding of 2.6, but
noted that the individual relative risk estimates were
heterogeneous, ranging from 1.4 to 11.2 [19]. This
review reported that the risk associated with aspirin was
not modified by age or gender. Meta-analysis of rando-
mized controlled trial data reports a pooled relative risk
for aspirin-associated bleeding of 1.6, with a range from
1.2 to 2.0 [20]. We elected to use a relative risk of 2 for
aspirin-associated bleeding risk because it came from
the same meta-analysis providing baseline bleeding risk.
The risk calculators utilized the “person-year” outcome,
which is most commonly interpreted as providing one-
year outcomes. However, one-year risks are sufficiently
low and may lead to patients undervaluing these out-
comes [21]. We therefore converted annualized outcome
rates to five-year risks using the declining exponential
approximation of life expectancy [22]. FileMaker Pro 9
Advanced (FileMaker, Inc, Santa Clara, CA) was used to
create a program that calculated and displayed these out-
come rates. The patient’s risk factors necessary to calcu-
late the risk of stroke and bleeding for each of the
treatment options are entered into a data entry screen,
prior to the encounter with the patient (Figure 3).
Although warfarin has been shown to decrease myo-
cardial infarction risk, [23] at our center, many patients
with coronary artery disease are prescribed aspirin,
regardless of whether or not they are taking warfarin.
To ensure that options presented were consistent with
local practice norms the tool was designed to show
patients the treatment options available to them
depending on whether or not they have coexisting cor-
onary artery disease. The addition of aspirin to warfarin
was assumed to confer no additional stroke risk reduc-
tion as compared to warfarin alone.
Patients without coronary artery disease are presented
with the options of no anticoagulation, aspirin alone,
and warfarin alone (Figure 4). According to their indivi-
dual comorbidities, patients’ 5 - y e a rr i s ko fs t r o k ew i t h
no therapy potentially ranges from 9 to 60%, with
aspirin from 7 to 51%, and with warfarin from 3 to 26%.
The 5-year risk of bleeding with warfarin potentially
ranges from 9 to 46%, with aspirin from 1 to 45%, and
with no therapy from 1 to 26%. Patients with coronary
artery disease who are currently taking aspirin are pre-
sented with the options of aspirin alone and aspirin plus
warfarin. Patients with coronary artery disease who are
taking warfarin alone are presented with the options of
aspirin alone and warfarin alone.
The practical issues related to each of the treatment
choices are also presented. No treatment and aspirin are
described as being associated with no need for regular
blood tests and no restriction of activities or diet. War-
farin is described as requiring monthly blood tests,
avoidance of activities that can cause serious injury, and
watching the amount of green, leafy vegetables in the
diet.
In addition, given that what matters most to patients
are not the risks of stroke or bleed per se, but the
sequelae of these, [24,25] we identified data describing
the outcome of stroke and major bleed in terms of mor-
tality and function [26,27].
“When people hear the word stroke, they might ima-
gine someone who can’t walk or who is in a nursing
home. This isn’t always the case. We can’tk n o wi n
advance how bad a stroke will be, but in general we
know that about half of all people who have a stroke
will recover, one-quarter will be disabled, and one-
quarter will die.”
“There are 2 types of major bleeding. These can hap-
pen inside your stomach or your brain. Patients with
major bleeding need to be hospitalized and have
blood transfusions. We can’t know in advance how
bad a bleed will be, but in general we know that
about three-quarters of all people who have a bleed
will recover, and a small number will be disabled or
die.”
To enable patients to consider the incremental risks
and benefits associated with each option, pictographs
illustrating the expected number of strokes and major
bleeds with each option are shown sequentially. Patients
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options on the same screen (Figure 5).
Empowering Patients to Understand the Importance of
their Participation
Helping patients to understand how their participation
results in improved treatment decisions can serve to
increase their awareness of the benefits of, and their
motivation for, engaging in informed choice. The chal-
lenge for decision tools is to help patients understand
the role of their values and preferences in the process
of decision making while acknowledging that many
patients do not want to be the primary decision maker.
To balance the need to help patients understand that
the “best” treatment for NVAF depends on each
patient’sv a l u e sw i t ht h er e c o g n i t i o nt h a tm a n y ,e s p e -
cially older, persons, rely on their physician’sr e c o m -
mendations and do not want to make the final
treatment decision, [28] we emphasized that the goal
of the tool was for both patients and physicians to
have a clear of understanding of how individual
patients value the outcomes related to each treatment
alternative:
“So as you can see, there is no perfect medication for
atrial fibrillation.
Because there is no perfect medication, there is no
single best choice for everyone. Each person will have
different opinions about the right balance between a
medication’sg o o de f f e c t sa n dam e d i c a t i o n ’sb a d
effects. You need to think about how important it is
to you to lower your risk of a stroke compared to the
risk of having a major bleed and the hassle of taking
coumadin.”
“It is important for your doctor to know how you feel
about these treatments. It will be important for you
to talk with your doctor about your concerns, ques-
tions, and opinions. Your doctor wants and needs to
know your thoughts about this, so that he/she can
make the best possible recommendation for you.”
 
Figure 3 Data entry screen.
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Figure 4 Presentation of outcome data for single treatment option.
 
Figure 5 Presentation of outcome data for all treatment options.
Fraenkel et al. BMC Medical Informatics and Decision Making 2011, 11:59
http://www.biomedcentral.com/1472-6947/11/59
Page 6 of 10“Talking about what’si m p o r t a n tt oy o uw i l lh e l p
your doctor make better treatment recommendations
for you.”
Developing Patients’ Communication Skills
The NVAF tool is built on the recognition that the final
treatment choice is best made through a process of
patient-clinician communication. It is designed to pro-
mote patients’ communication skills by including multi-
ple opportunities for them to engage in conversation
with the facilitator throughout the tool [11]. The tool
opens with a screen consisting of a series of photo-
graphs of patients and physicians talking to one another.
Participants are asked to describe what they are seeing
in the photographs, while the accompanying script high-
lights both the importance and challenges of good
patient-physician communication:
“How well you and your doctor talk to each other is
one of the most important parts of getting good
health care. But sometimes talking to your doctor is
not easy because you’re not sure what to say.”
The tool also asks patients to think about each treat-
ment option by discussing their views on the benefits
and harms. This approach helps patients to clarify their
values in the context of practicing what they may want
to communicate to their physician. If they have difficulty
answering, the research assistant encourages them by
saying:
“Let’s think about them one at a time. What are your
feelings about aspirin? What do you like about that
as a treatment and what do you dislike?”
The final section directly prepares participants for
communicating with their physicians by asking them to
write down specific questions they would like to ask in
the form of a worksheet.
“Let’s think about what questions or comments you
might have for your doctor. I’d like you to write them
down here.”
Providing Patients with the Opportunity to Participate
There is ample evidence in the literature that patients,
including those that perceive themselves as empowered,
frequently fail to attain their desired level of participa-
tion [29]. Some patients do not have effective communi-
cation skills while others may simply not be afforded
the opportunity [30]. These findings support the need
for decision support tools to target physician, as well as
patient, communication. In order to increase the prob-
ability that patients are given the opportunity to partici-
pate, the tool includes a prompt for physicians to use
during the encounter:
“I know you just learned about your treatment
options for your Afib. Can you tell me how you feel
about them?”
The prompt, which is handed to the physician by the
facilitator as the patient enters the examination room
for the clinical visit, was created to ensure that the deci-
sion support tool exert an effect on the “real-time” clini-
cal interaction between doctor and patient. This
interaction serves several purposes. For example, the
clinician can assess patient’s knowledge regarding differ-
ent treatment options and address any misperceptions
the patient may have. With their knowledge of the indi-
vidual patient’s clinical and psychosocial status, clini-
cians can help patients to understand better how his/her
values and preferences can best inform decision making.
An alternative approach to providing patients with the
opportunity to participate is to create entire tools for
use by the physician within the clinical visit. However,
physicians’ time constraints make it difficult to routinely
include these tools in clinical practice. The proposed
model, and design of the NVAF tool, is consistent with
the goals and organization of the patient-centered medi-
cal home in which all members of the patient’s health-
care team utilize their top skill sets [31]. The initial part
of the tool, focusing on patient preparation, can be
administered by a nurse or other mid-level practitioner.
The completion of the worksheet, along with a specific
physician prompt, are designed to extend the reach of
the tool, both literally and figuratively, into the clinical
encounter during which time the physician can actively
engage the informed and prepared patient in the deci-
sion making process.
Feasibility and Acceptability
The computer tool underwent testing for feasibility and
acceptability with participants identified as having had a
primary care visit at the VA Connecticut Healthcare
System with a diagnosis code for atrial fibrillation within
the last 24 months. Charts were reviewed to confirm the
diagnosis of NVAF and for exclusion criteria, which
included: a) diagnosis of dementia, b) legal blindness,
and c) contraindication to warfarin or aspirin. The clini-
cians for potential participants were also asked to indi-
cate whether their patients met any of the following
exclusion criteria: a) atrial fibrillation managed by a phy-
sician outside of the VA, b) the patient would not be
able to understand numeric data based on cognitive
impairment, c) the patient had a life expectancy of < 12
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clock-drawing task performed at the start of their study
participation.
Eligible participants met with a trained research nurse
immediately prior to a regularly scheduled primary care
visit to complete the computer tool. Just after complet-
ing the tool, participants were asked about its ease of
use and acceptability.
A total of 11 participants used the tool. Participants
had mean age of 78 ± 9 years (range 61-90), and 7
(64%) had completed ≤ 12 years of education. The tool
took between 20 and 35 minutes to administer. On a
scale from 1 to 5, ranging from very easy to very hard, 8
(72%) rated the ease of completing the tool as a 1, with
no participant rating the ease of the tool as > 3. When
asked about the amount of information provided by the
tool on a scale of 1 to 5, with 1 = “too little,” 3=“just
right,” and 5 = “too much,” 9 (81%) participants rated
the amount as 3, and 2 participants rated the amount as
2. When asked if they would recommend the tool to
others, 10 (91%) responded “yes.”
Discussion
The development of a new decision support tool for
anticoagulation for NVAF was based on the desire to
provide patients with individualized outcome data
regarding their risks of stroke and bleeding associated
with all reasonable treatment options. It sought to pro-
vide these data in the context of preparing patients to
participate in the decision-making process with their
physicians by helping them to understand why treat-
ment of NVAF involves a choice and the role of their
values in the decision and by encouraging patient-physi-
cian communication. In pilot testing, the majority of
participants reported that the tool was easy to complete
and contained the right amount of information, and that
they would recommend the tool to a friend.
Embedded within the tool is a risk calculator which
provides patients with individualized outcomes related
to all available alternatives over a meaningful time per-
iod. Building upon the work of prior tools [9,10,32] to
provide patients with individualized outcomes of stroke
risk, the tool uses the best available current observa-
tional data to individualize bleeding risk according to
the patient’s specific comorbidity profile. There is wide
variability in both stroke and bleeding risk, and, because
different comorbidities are associated with stroke and
bleeding, the benefit-to-harm ratio can reverse depend-
ing upon the particular combination of comorbid condi-
tions [6]. This tool allows patients to consider explicitly
the trade-offs between the reduction in stroke risk ver-
sus increase in bleeding risk associated with different
treatment options, with each of these risks separately
calculated for each individual patient. In addition, we
provide patients with an explicit description of the
sequelae associated with both stroke and major bleed.
The tool also helps patients to understand the impor-
tance of their values in decision making for NVAF. The
language we employed is careful to reflect the finding
that almost all patients count on their physicians’
recommendations and many patients may not want to
make treatment decisions for themselves [28,33]. The
objective is to have patients communicate their views
regarding the trade-offs among the different treatment
options to their physicians, so that a decision can be
made according to the preferred decision-making style
of the patient, which may be to share in making the
decision or to have the physician make the decision.
Addressing the quality of physician-patient communica-
tion requires intervening both on the part of the patient
and the physician. The tool is built on the recognition
that patients’ communication styles can have a substan-
tial influence on physicians’ behavior [34] and that,
through intervention aimed at preparing patients with
appropriate questions, patients’ communication skills
can be improved such that they give more information
to and receive more information from their physicians
[35]. The tool also acknowledges that patients, including
those that perceive themselves as empowered, frequently
fail to attain their desired level of participation, [36,37]
by including a physician prompt that invites patient
communication.
There are several limitations in the individualized risk
information the tool provides. First, both the CHADS2
and HEMORR2HAGES scores were based on Medicare
data, and their validity for use among younger patients
has not been established. Second, the relative risk of
bleeding with aspirin is assumed to be constant across
all individuals, which does not allow for the possibility
of interactions between aspirin and bleeding risk factors.
Moreover, we did not address the known interactions
between warfarin and other medications, such as
NSAIDs. Third, although we elected not to use rando-
mized controlled trial data to describe the probability of
intracranial versus extracranial bleeding, the differences
in mortality and functional sequelae of these two out-
comes suggest that they should be presented as two dis-
tinct outcomes. Finally, it is likely that the bleeding risk
associated with warfarin decreases over time,[38] but we
did not have sufficient data to calculate a differential
bleeding risk over time.
Conclusions
Building upon the work of earlier tools, this new deci-
sion support tool provides individualized outcome data
for stroke and bleeding risk associated with all appropri-
ate treatment options, and it incorporates elements
designed to promote physician-patient communication.
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of the tool on knowledge and decisional conflict, out-
comes routinely included in and improved by decisions
support tools [39]. The tool has also been designed to
achieve the goal of improving the quality of decision-
making for NVAF by ensuring that the decision incor-
porates the informed patient’sv a l u e s .T h i so u t c o m eh a s
not frequently been included in studies of decision sup-
port tools [39]. The challenge for future intervention
trials is how to measure this outcome, which depends
upon the complex interplay of the patient’s understand-
ing of his/her illness, the patient’s values and prefer-
ences, and the opinions and preferences of the
physician.
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